What's Happening Now is a quick, thoughtful, real-time briefing regarding material events in the stem cell industry...definitely not the usual stream of insignificant press releases. The most current Happenings are boxed on the left-hand side of most pages on this site. Feel free to use this page to explore the archive of all past Happening items, and subscribe to the RSS feed to stay on top of the events that move the market and the industry.
Who Is Cytori's new partner, Lorem Vascular?
Nov 5, 2013
Cytori Soars on News of Asia Deal
Nov 5, 2013
(CYTX) shares were up over 60% on news
of a deal with China's Lorem Vascular. Lorem will exclusively license the Celution System for a broad range of medical indications in China, Hong Kong, Malaysia, Singapore and Australia. The deal involves upfront payments to Cytori of $14 million, plus contingent payments and royalties that could reach $500 million over 30 years.
Cytori's ADVANCE Trial Update Reveals Chronic Recruiting Problem
Oct 8, 2013
(CYTX) latest update
to the ClinicalTrials.gov record of its now abandoned ADVANCE trial for myocardial infarction reveals that just 23 patients (of an original goal of 360) were recruited to the trial in over 2 years of effort, validating the Nov. 2012 red flag (for insufficient progress) given this trial by our Clinical Trials Monitor
, when CYTX shares were 55% higher than today.
Cytori To Terminate European Heart Attack Trial
Aug 12, 2013
In its quarterly business update, Cytori
it will terminate its European heart attack trial, ADVANCE. The news validates the red-flag downgrade our Clinical Trials Monitor
assigned this trial as of late 2012.
Cytori Sells Off PureGraft Product Line
Jul 31, 2013
the sale of its Puregraft product line ("designed to streamline the fat graft preparation process by selectively washing and filtering the tissue") to start-up Bimini Technologies, founded by Cytori alumni, for $5M upfront plus milestone payments. The transaction frees Cytori to focus exclusively on stem cells.
Cytori goes it alone
May 10, 2013
< Previous Page
In its quarterly results release
revealed it is buying out its joint venture partner, Olympus. The company reports less than a year of cash on hand.
| Next Page >